-
Dutch Cost Implications of Faricimab in Neovascular Age-Related Macular Degeneration: A Systematic Review of Treatment Interval and Injection Frequency
Sep 9, 2025, 16:22 PM -
Avacopan in the Treatment of ANCA-Associated Vasculitis: A Cost-Utility Analysis in Portugal
Sep 9, 2025, 16:22 PM -
The Acceptability of Wearables in Remote Monitoring According to Health Technology Assessment HTA Bodies
Sep 9, 2025, 16:22 PM -
Understanding the Consequences of International Reference Pricing on Cancer Immunotherapy in Europe: A 10-Year Price Corridor Analysis
Sep 9, 2025, 16:22 PM -
Network Meta-Analysis of Survival Outcomes in the First-Line Treatment of Unresectable or Metastatic Melanoma: Scoping Review of Methodology
Sep 9, 2025, 16:22 PM -
Sedative-Hypnotic Drug Use and Polypharmacy Patterns Associated With Risk of Falls and Fractures in Older Adults by Osteoporosis Status: A Korean Nationwide Senior Cohort Study
Sep 9, 2025, 16:22 PM -
Accounting for the Additional Uncertainty Following Rank-Preserving Structural Failure Time Model (RPSFTM) Crossover Adjustment in Survival Analysis: A Sage Approach
Sep 9, 2025, 16:22 PM -
Evolving Assumptions on Treatment Durability in Cost-Effectiveness Models of Cell and Gene Therapies: Insights From French HTA Submissions
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Ribociclib With Endocrine Therapy for Treatment With Premenopausal Women With HR Positive HER2 Negative Early Breast Cancer in the UK
Sep 9, 2025, 16:22 PM -
Investigating Functional Status and Healthcare Resource Utilization of Patients With Cognitive Impairment Associated With Schizophrenia: Findings From a Real-World Noninterventional Study
Sep 9, 2025, 16:22 PM -
Bayesian Dynamic Borrowing to Enhance Evidence for New Therapies
Sep 9, 2025, 16:22 PM -
The Impact of the Introduction of Diagnosis-Related Groups (DRG)-Based Hospital Financing on the Performance of Romanian Hospitals
Sep 9, 2025, 16:22 PM -
Budget Impact of Azathioprine Metabolite Monitoring in Crohn’s Disease in Algeria
Sep 9, 2025, 16:22 PM -
Effectiveness of Subcutaneous Natalizumab in Multiple Sclerosis: Real-World Evidence From a Finnish Registry Study
Sep 9, 2025, 16:22 PM -
Informing Health System Reform Through Patient Perspectives: Saudi Arabia’s OECD Paris Survey Results
Sep 9, 2025, 16:22 PM -
What Are the Impacts of the Absence of Health Economic Evaluations for Drugs Granted an ASMR IV Rating by the French National Authority of Health (HAS)? An Analysis of Medicines Assessed Between May 2022 and May 2024
Sep 9, 2025, 16:22 PM -
Transforming Pediatric Type 1 Diabetes Care in Bulgaria Through Structured Patient Journey Analysis
Sep 9, 2025, 16:22 PM -
extRpolateS: A Shiny-Based Interactive Platform for Time-to-Event Data Modeling in Health Technology Assessments
Sep 9, 2025, 16:22 PM -
Investing in Diagnosis: Health Economic Value of Early Obstructive Sleep Apnea Detection for Private Insurers in India
Sep 9, 2025, 16:22 PM -
Resource Utilization Among Patients With Epidermolysis Bullosa: Preliminary Findings From Seven European Countries
Sep 9, 2025, 16:22 PM
